{
  "pathway_name": "molecular-testing-provisional-recommendations-v11-2024",
  "original_file": "molecular-testing-provisional-recommendations-v11-2024_extracted.json",
  "processed_at": "2025-03-29T01:38:26.920118",
  "complete_summary": {
    "response": "# Comprehensive Clinical Pathway: Molecular Testing Provisional Recommendations (v11-2024)\n\n## EXECUTIVE SUMMARY\nThis clinical reference document outlines standardized molecular testing recommendations for solid tumors and hematologic malignancies. It specifies appropriate testing methodologies, specimen requirements, vendor options, and coverage information to guide evidence-based diagnostic approaches for oncology patients.\n\n---\n\n## I. SOLID TUMORS\n\n### A. Cervical Carcinoma\n**ELIGIBILITY**: Persistent, Recurrent, or Metastatic Disease\n\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Tumor Tissue Testing**:\n   - PD-L1 IHC (clone 22C3 with CPS scoring)\n   - MMR protein IHC (MLH1, MSH2, MSH6, PMS2)\n   - MSI testing by PCR\n\n2. **Reflex Testing**:\n   - If MLH1/PMS2 loss detected: Perform MLH1 promoter hypermethylation testing\n     * Hypermethylated \u2192 Indicates sporadic mutation\n     * Unmethylated \u2192 Proceed to germline testing\n\n3. **Germline Testing Indications**:\n   - MSH2/MSH6 loss on IHC\n   - MLH1/PMS2 loss with unmethylated MLH1 promoter\n   - MSI-High status with unmethylated MLH1 promoter\n   \n**SPECIMEN REQUIREMENTS**: Tumor tissue for IHC/MSI; blood/saliva for germline testing\n\n### B. Ovarian, Fallopian Tube & Primary Peritoneal Carcinomas\n**TESTING STRATIFICATION BY STAGE AND HISTOLOGY**:\n\n1. **Endometrioid Histology, Stage I**:\n   - MMR protein IHC (MLH1, MSH2, MSH6, PMS2)\n   - MSI testing by PCR\n\n2. **All Histologies, Stage II-IV**:\n   - MMR protein IHC\n   - Comprehensive Genomic Profiling (CGP) using DNA and RNA-based methodology\n\n3. **Universal Testing (All Histologies/Stages)**:\n   - Germline NGS panel for hereditary cancer risk assessment\n\n**SPECIMEN REQUIREMENTS**: Tumor tissue for somatic testing; blood/saliva for germline testing\n\n### C. Paraganglioma or Pheochromocytoma\n**RECOMMENDED TESTING**:\n- Germline NGS panel testing regardless of disease stage\n\n**SPECIMEN REQUIREMENTS**: Blood or saliva\n\n### D. Thyroid Carcinoma\n**TESTING STRATIFICATION**:\n\n1. **Advanced or Metastatic Carcinoma**:\n   - Comprehensive Genomic Profiling (CGP) using DNA and RNA-based methodology\n\n2. **Medullary Thyroid Carcinoma (any stage)**:\n   - Germline NGS panel testing\n\n**SPECIMEN REQUIREMENTS**: Tumor tissue for somatic testing; blood/saliva for germline testing\n\n---\n\n## II. HEMATOLOGIC MALIGNANCIES\n\n### A. Anaplastic Large Cell Lymphoma (ALCL)\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Evaluation**:\n   - IHC for ALK, CD30, T-cell markers, and PAX5\n\n2. **ALK Status Decision Point**:\n   - ALK-positive \u2192 Complete diagnosis as ALK+ ALCL\n   - ALK-negative \u2192 Perform FISH analysis for:\n     * TP63 rearrangement\n     * DUSP22 rearrangement\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy, lymph node biopsy, or blood\n\n### B. B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL/LBL)\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Evaluation**:\n   - Flow cytometry with B-ALL MRD testing capability\n   - FISH panel including BCR-ABL1 t(9;22)\n   - Conventional karyotyping\n   - BCR-ABL1 quantitative PCR (both p190 and p210)\n\n2. **Secondary Evaluation (if necessary)**:\n   - Additional FISH probes if karyotype normal/uninformative:\n     * 11q23 KMT2A (MLL) rearrangement\n     * Chromosomal gains (+4, +10, +17)\n     * t(1;19) TCF3-PBX1\n     * 14q32 IGH rearrangement\n     * del(9p) CDKN2A deletion\n\n3. **For Unclassified Cases**:\n   - Consider Comprehensive Genomic Profiling if no driver mutation detected\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy or blood\n\n### C. Burkitt Lymphoma\n**DIAGNOSTIC ALGORITHM**:\n1. **Immunophenotypic Assessment**:\n   - IHC/Flow for CD10, CD19, CD20, CD43, BCL2, BCL6, Ki-67, MYC, TdT, and light chains\n\n2. **Genetic Assessment**:\n   - FISH for IGH::MYC fusion\n   - If negative \u2192 FISH for IGK::MYC or IGL::MYC\n\n3. **Viral Assessment**:\n   - ISH for EBER (Epstein-Barr virus)\n\n4. **For Morphologically Consistent but MYC-Negative Cases**:\n   - Array CGH or FISH for 11q abnormalities to evaluate for Burkitt-like lymphoma\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy, lymph node biopsy, or blood\n\n### D. CMML and MDS/MPN\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Assessment**:\n   - Flow cytometry (consider monocyte subset analysis)\n   - FISH for BCR-ABL1 t(9;22) to rule out CML\n   - Conventional karyotyping\n\n2. **When Morphology Consistent with MDS/MPN**:\n   - Targeted myeloid NGS panel including:\n     * ASXL1, BCOR, CBL, DNMT3A, ETV6, EZH2, TET2, SRSF2, etc.\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy or blood\n\n### E. Eosinophil-Related Malignancies\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Evaluation**:\n   - Flow cytometry (including T-cell phenotyping to rule out lymphocytic variant-HES)\n   - FISH for BCR-ABL1 t(9;22) to rule out CML\n   - Optional FISH for inv(16)/t(16;16) if AML suspected\n   - Conventional karyotyping\n\n2. **Reflex Testing Based on Initial Findings**:\n   - If abnormal T-cells detected \u2192 T-cell clonality testing\n   - If myeloproliferative features present \u2192 Myeloid NGS panel and RNA-based fusion panel including PDGFRA, PDGFRB, FGFR1, JAK2\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy or blood\n\n### F. Immunosuppression-Related/HHV8/EBV-Related Lymphoma\n**RECOMMENDED TESTING**:\n- Consider HIV serological testing\n\n**SPECIMEN REQUIREMENTS**: Blood\n\n### G. Mixed Phenotype Acute Leukemia (MPAL) or Undifferentiated Leukemia\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Diagnostic Evaluation**:\n   - Flow cytometry\n   - FISH for BCR-ABL1, KMT2A, -5/5q, -7/7q\n   - Conventional karyotyping\n\n2. **Molecular Testing**:\n   - BCR-ABL1 qPCR (if FISH positive)\n   - Rapid molecular tests (results within 1 week):\n     * FLT3 ITD and TKD\n     * IDH2\n     * NPM1\n     * CEBPA (optional)\n\n3. **Comprehensive Testing**:\n   - RNA and DNA-based Comprehensive Genomic Profiling\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy or blood\n\n### H. Post-Transplant Lymphoproliferative Disorder (PTLD)\n**RECOMMENDED TESTING**:\n- CD30 IHC\n- EBER in-situ hybridization for EBV detection\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy, lymph node biopsy, or blood\n\n### I. Systemic Mastocytosis\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Evaluation**:\n   - Serum tryptase measurement\n   - IHC for CD117, tryptase, CD2, CD25, CD30\n   - Flow cytometry with mast cell phenotyping\n   - Conventional karyotyping\n   - KIT D816V mutation testing (high sensitivity)\n\n2. **Systemic Mastocytosis with Morphologic Confirmation**:\n   - Targeted myeloid NGS panel\n\n3. **Systemic Mastocytosis with Significant Eosinophilia**:\n   - Targeted myeloid NGS panel\n   - RNA-based fusion panel including PDGFRA, PDGFRB, FGFR1, JAK2\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy, blood\n\n### J. T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)\n**DIAGNOSTIC ALGORITHM**:\n1. **Initial Evaluation**:\n   - Flow cytometry\n   - FISH for TRB/TRD rearrangements and CDKN2A loss\n   - Conventional karyotyping\n\n2. **For Treatment-Refractory Cases**:\n   - Consider Comprehensive Genomic Profiling\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy or blood\n\n### K. T-Cell and NK-Cell Leukemias/Lymphomas\n**DIAGNOSTIC APPROACH BY SUBTYPE**:\n\n1. **T-Prolymphocytic Leukemia/Lymphoma (TPLL)**:\n   - IHC/Flow: T-cell markers including TCL1a\n   - Consider FISH for TCL1a rearrangements\n   - T-cell clonality testing if needed for diagnosis\n\n2. **Adult T-cell Leukemia/Lymphoma (ATLL)**:\n   - IHC/Flow: T-cell markers including CD25 and FOXP3\n   - HTLV-1 serology\n   - T-cell clonality testing if needed\n\n3. **Angioimmunoblastic T-cell Lymphoma (AITL) and Follicular T-Helper Lymphomas**:\n   - IHC/Flow: T-cell markers including TFH antigens (CD10, BCL6, PD1, CXCL13, ICOS)\n   - Consider in-situ hybridization\n   - T-cell clonality testing if needed\n\n4. **T-Cell Large Granular Lymphocytic Leukemia (T-LGL)**:\n   - IHC/Flow: T-cell markers including CTL antigens (CD8, CD56, CD16, CD57, granzyme B, perforin)\n   - T-cell clonality testing if needed\n\n5. **Hepatosplenic T-Cell Leukemia (HSTCL)**:\n   - IHC/Flow: T-cell markers including TCR\u03b1\u03b2, TCR\u03b3\u03b4 markers\n   - T-cell clonality testing if needed\n\n6. **Aggressive NK-Cell Leukemia (ANKL)**:\n   - IHC/Flow: NK-cell markers (CD2, CD7, CD16, CD56, KIRs)\n   - EBER in-situ hybridization\n   - T-cell clonality to exclude T-cell leukemia\n\n7. **Extranodal NK/T-Cell Lymphoma (ENKTL)**:\n   - IHC/Flow: NK-cell markers\n   - EBER in-situ hybridization\n\n8. **NK-Cell Large Granular Lymphocytic Leukemia (NK-LGL)**:\n   - IHC/Flow: NK-cell markers\n   - T-cell clonality to exclude T-LGL\n\n**SPECIMEN REQUIREMENTS**: Bone marrow biopsy, lymph node biopsy, or blood\n\n---\n\n## III. OPERATIONAL CONSIDERATIONS\n\n### A. Specimen Selection\n- Most tests accept either bone marrow biopsy, lymph node biopsy, or blood specimens\n- NGS testing can often be performed on peripheral blood if bone marrow is unavailable\n- Fresh tissue is preferred for RNA-based testing\n- Consider concurrent blood collection for germline testing when indicated\n\n### B. Vendor Selection\n- **Basic Testing**: Local VA or locally contracted vendors\n- **Comprehensive Genomic Profiling**: Foundation Medicine, Tempus\n- **Germline Testing**: Fulgent Genetics\n- **Regional Reference Centers**: GLA (Greater Los Angeles) for specific testing\n\n### C. Coverage Information\n- **NPOP Coverage**: Primarily available for advanced molecular testing\n- **Non-NPOP Covered Tests**: Most IHC, FISH, and basic molecular tests\n- **Grant Options**: GLA Grant may be available for specialized NGS testing (requires outreach)\n\n### D. Critical Clinical Considerations\n- Specimen adequacy assessment is essential before testing\n- Consider pre-test probability when ordering comprehensive panels\n- Correlate molecular findings with morphology and immunophenotype\n- For rare or diagnostically challenging cases, consider consultation with specialized reference centers\n- Germline testing requires appropriate pre-test genetic counseling\n\nThis clinical pathway document represents the current (2024) standard of care for molecular testing in oncology and should be updated as evidence evolves.",
    "thinking": "I'll create a comprehensive summary of the clinical pathway for molecular testing in oncology based on all the analyses provided. I'll structure this summary to be clinically relevant and useful as a reference document for healthcare providers.\n\nThe document appears to focus on molecular testing recommendations for various oncologic conditions, organized into two main sections: Solid Tumors and Hematologic Malignancies. I'll create a comprehensive summary that preserves this organization while highlighting key testing recommendations, decision points, and clinical workflows.\n\nLet me create an organized, detailed summary:\n\n# Molecular Testing Provisional Recommendations (v11-2024)\n\n## Overview\nThis clinical pathway provides guidance on appropriate molecular testing for various solid tumors and hematologic malignancies. The document outlines specific test types, specimen requirements, preferred vendors, and coverage status (NPOP - National Pathology and Laboratory Medicine Program).\n\n## I. SOLID TUMORS\n\n### A. Cervical Carcinoma\n**Eligibility: Persistent, Recurrent, or Metastatic Disease**\n\n**Testing Sequence:**\n1. **Primary Tumor Tissue Testing**\n   - **Immunohistochemistry (IHC)**\n     - PD-L1 clone 22C3 with CPS\n     - Mismatch Repair Proteins (MLH1, MSH2, MSH6, PMS2)\n   - **PCR Testing**\n     - Microsatellite instability (MSI) status\n\n2. **MLH1 Loss Follow-up**\n   - If loss of MLH1 or PMS2 expression detected by IHC:\n     - MLH1 promoter hypermethylation testing\n     - If hypermethylated \u2192 Suggests somatic mutation\n     - If unmethylated \u2192 Proceed to Germline Lynch testing\n\n3. **Germline Testing Pathway**\n   - Indications:\n     - MSH2 or MSH6 loss detected by IHC\n     - MLH1 or PMS2 loss by IHC AND MLH1 unmethylated\n     - MSI-High (MSI-H) without IHC testing AND MLH1 unmethylated\n   - Test: Germline Lynch Syndrome testing (via Fulgent Genetics)\n\n### B. Ovarian, Fallopian Tube & Primary Peritoneal Carcinomas\n**Testing stratified by histology and stage:**\n\n1. **Endometrioid Histology, Stage I:**\n   - IHC for MMR proteins (MLH1, MSH2, MSH6, PMS2)\n   - PCR for MSI status\n\n2. **All Histologies, Stage II-IV:**\n   - IHC for MMR proteins\n   - Comprehensive Genomic Profiling (CGP) using both DNA and RNA based methodology\n\n3. **All Histologies, All Stages:**\n   - Germline NGS panel (for hereditary cancer risk assessment)\n\n### C. Paraganglioma or Pheochromocytoma\n**Testing recommendation:**\n- Germline NGS panel (via Fulgent) using blood or saliva specimens\n\n### D. Thyroid Carcinoma\n**Testing stratified by disease type:**\n\n1. **Advanced or Metastatic Carcinoma:**\n   - Somatic NGS: Comprehensive Genomic Profiling (CGP) using both DNA and RNA based methodology\n\n2. **Medullary Thyroid Carcinoma (any stage):**\n   - Germline NGS panel using blood or saliva specimens\n\n## II. HEMATOLOGIC MALIGNANCIES\n\n### A. Anaplastic Large Cell Lymphoma (ALCL)\n**Diagnostic Testing Algorithm:**\n\n1. **Primary IHC Testing:**\n   - ALK, CD30, T-cell markers, PAX5\n\n2. **ALK Status Assessment:**\n   - If ALK-positive \u2192 Complete diagnosis as ALK-positive ALCL\n   - If ALK-negative \u2192 Proceed to additional molecular testing:\n     - FISH analysis for TP63 and DUSP22 rearrangements\n\n### B. B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL/LBL)\n**Diagnostic Testing Framework:**\n\n1. **Flow Cytometry:**\n   - Leukemia/lymphoma panel with B-ALL minimal residual disease (MRD) capability\n\n2. **Cytogenetic Analysis:**\n   - FISH: B-ALL diagnostic panel that includes t(9;22) BCR-ABL1\n   - Optional FISH probes: 11q23 KMT2A, +4/+10/+17, t(1;19) TCF3-PBX1, 14q32 IGH, del(9p) CDKN2A\n   - Karyotyping: Standard chromosomal analysis\n\n3. **Molecular Testing:**\n   - BCR-ABL1 quantitative PCR (p190 and p210 isoforms)\n   - Consider Comprehensive Genomic Profiling if no driver mutation detected\n\n### C. Burkitt Lymphoma\n**Diagnostic Testing Pathway:**\n\n1. **Immunophenotypic Assessment:**\n   - IHC or Flow Cytometry for CD10, CD19, CD20, CD43, BCL2, BCL6, Ki-67, MYC, TdT, and surface immunoglobulin light chains\n\n2. **Genetic Assessment:**\n   - FISH analysis for IGH::MYC fusion\n   - If negative, proceed to FISH for IGK::MYC or IGL::MYC\n\n3. **Viral Assessment:**\n   - ISH for EBER (Epstein-Barr virus)\n\n4. **For Burkitt-like lymphoma (MYC-negative):**\n   - Array CGH or FISH for 11q abnormalities\n\n### D. Chronic Myelomonocytic Leukemia (CMML) and MDS/MPN\n**Diagnostic Testing Approach:**\n\n1. **Initial Testing:**\n   - Flow Cytometry (consider monocyte subset analysis)\n   - FISH for BCR-ABL1 (to rule out CML)\n   - Bone marrow karyotype\n\n2. **For MDS/MPN morphology:**\n   - Somatic NGS: Targeted myeloid panel including ASXL1, BCOR, CBL, DNMT3A, TET2, and many others\n\n### E. Eosinophil Related Malignancies\n**Diagnostic Testing Pathway:**\n\n1. **First-line Testing:**\n   - Flow Cytometry: Leukemia/lymphoma panel with T cell phenotyping\n   - FISH: BCR-ABL1 t(9;22) to rule out CML\n   - Optional FISH: inv(16) or t(16;16) CBFB/MYH11 if AML suspected\n   - Karyotyping: Bone marrow karyotype\n\n2. **If abnormal T-cells detected:**\n   - T-cell clonality testing\n\n3. **For Myeloproliferative Neoplasm morphology:**\n   - Somatic NGS: Targeted myeloid panel\n   - RNA-based Fusion panel including PDGFRA, PDGFRB, FGFR1, JAK2, ABL1\n\n### F. Immunosuppression-Related/HHV8/EBV-Related Lymphoma\n**Testing recommendation:**\n- Consider HIV serological testing\n\n### G. Mixed Phenotype Acute Leukemia (MPAL) or Undifferentiated Leukemia\n**Diagnostic Testing Protocol:**\n\n1. **Initial Diagnostic Evaluation:**\n   - Flow Cytometry: Leukemia/lymphoma panel on bone marrow\n   - FISH: BCR-ABL1, KMT2A rearrangement, -5/5q; -7/7q\n   - Karyotyping: Bone marrow karyotype\n\n2. **Molecular Testing:**\n   - qPCR for BCR-ABL1 (if FISH positive)\n   - Rapid molecular tests (within 1 week): FLT3 ITD and TKD, IDH2, NPM1, CEBPA (optional)\n\n3. **Comprehensive Genomic Profiling:**\n   - Somatic NGS: RNA and DNA based CGP\n\n### H. Post-Transplant Lymphoproliferative Disorder (PTLD)\n**Diagnostic Testing:**\n- IHC: CD30\n- ISH: EBER (for Epstein-Barr virus detection)\n\n### I. Systemic Mastocytosis\n**Diagnostic Testing Algorithm:**\n\n1. **Initial Assessment:**\n   - Serology: Serum Tryptase\n   - IHC: CD117, tryptase, CD2, CD25, CD30\n   - Flow Cytometry: Leukemia/lymphoma panel with mast cell phenotyping\n   - Karyotyping: Bone marrow karyotype\n   - Molecular Testing: KIT D816V mutation\n\n2. **For Consistent Morphology:**\n   - Somatic NGS: Targeted myeloid panel\n\n3. **For Systemic Mastocytosis with Significant Eosinophilia:**\n   - Somatic NGS: Targeted myeloid panel\n   - RNA-based Fusion panel\n\n### J. T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)\n**Diagnostic Testing Pathway:**\n\n1. **Initial Evaluation:**\n   - Flow Cytometry: Leukemia/lymphoma panel\n   - FISH: T-ALL panel (TRB/TRD rearrangements, CDKN2A loss)\n   - Karyotyping: Bone marrow karyotype\n\n2. **For Treatment-Refractory Cases:**\n   - Somatic NGS: Consider Comprehensive Genomic Profiling\n\n### K. T-Cell and NK-Cell Leukemias/Lymphomas\n**Diagnosis-specific Testing Approach:**\n\n1. **T-Prolymphocytic Leukemia/Lymphoma (TPLL):**\n   - IHC/Flow: T-cell markers including TCL1a\n   - FISH: Consider TCL1a rearrangements\n   - Molecular: T-cell clonality if needed\n\n2. **Adult T-cell Leukemia/Lymphoma (ATLL):**\n   - IHC/Flow: T-cell markers including CD25 and FOXP3\n   - Serology: HTLV-1 testing\n   - Molecular: T-cell clonality if needed\n\n3. **Angioimmunoblastic T-cell Lymphoma (AITL):**\n   - IHC/Flow: T-cell markers including TFH antigens\n   - FISH: Consider in situ hybridization\n   - Molecular: T-cell clonality if needed\n\n4. **T-Cell Large Granular Lymphocytic Leukemia (T-LGL):**\n   - IHC/Flow: T-cell markers including CTL antigens\n   - Molecular: T-cell clonality if needed\n\n5. **Hepatosplenic T-Cell Leukemia (HSTCL):**\n   - IHC/Flow: T-cell markers including TCR\u03b1\u03b2, TCR\u03b3\u03b4\n   - Molecular: T-cell clonality if needed\n\n6. **Aggressive NK-Cell Leukemia (ANKL):**\n   - IHC/Flow: NK-cell markers\n   - FISH: EBER in situ hybridization\n   - Molecular: T-cell clonality to rule out T-cell leukemia\n\n7. **Extranodal NK/T-Cell Lymphoma (ENKTL):**\n   - IHC/Flow: NK-cell markers\n   - FISH: EBER in situ hybridization\n\n8. **NK-Cell Large Granular Lymphocytic Leukemia (NK-LGL):**\n   - IHC/Flow: NK-cell markers\n   - Molecular: T-cell clonality to rule out T-LGL\n\n## General Considerations\n\n1. **Specimen Selection:**\n   - Most tests can be performed on either bone marrow biopsy, lymph node biopsy, or blood specimens\n   - NGS testing can often be performed on peripheral blood if bone marrow is unavailable\n\n2. **Testing Vendors:**\n   - Local VA or locally contracted vendors are recommended for most basic testing\n   - Foundation Medicine and Tempus are frequently recommended for comprehensive genomic profiling\n   - Fulgent Genetics is the preferred vendor for germline testing\n\n3. **Coverage Information:**\n   - Advanced molecular testing is typically covered under NPOP\n   - Basic testing (IHC, FISH, etc.) is typically not covered under NPOP\n   - GLA Grant may be available for some specialized NGS testing\n\nNow I'll refine this into a well-organized clinical pathway summary that would be useful for clinicians:"
  }
}